Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 105

1.

Which ante mortem clinical features predict progressive supranuclear palsy pathology?

Respondek G, Kurz C, Arzberger T, Compta Y, Englund E, Ferguson LW, Gelpi E, Giese A, Irwin DJ, Meissner WG, Nilsson C, Pantelyat A, Rajput A, van Swieten JC, Troakes C, Josephs KA, Lang AE, Mollenhauer B, Müller U, Whitwell JL, Antonini A, Bhatia KP, Bordelon Y, Corvol JC, Colosimo C, Dodel R, Grossman M, Kassubek J, Krismer F, Levin J, Lorenzl S, Morris H, Nestor P, Oertel WH, Rabinovici GD, Rowe JB, van Eimeren T, Wenning GK, Boxer A, Golbe LI, Litvan I, Stamelou M, Höglinger GU; Movement Disorder Society-Endorsed PSP Study Group.

Mov Disord. 2017 May 13. doi: 10.1002/mds.27034. [Epub ahead of print]

PMID:
28500752
2.

Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?

Whitwell JL, Höglinger GU, Antonini A, Bordelon Y, Boxer AL, Colosimo C, van Eimeren T, Golbe LI, Kassubek J, Kurz C, Litvan I, Pantelyat A, Rabinovici G, Respondek G, Rominger A, Rowe JB, Stamelou M, Josephs KA; Movement Disorder Society-endorsed PSP Study Group.

Mov Disord. 2017 May 13. doi: 10.1002/mds.27038. [Epub ahead of print] Review.

PMID:
28500751
3.

Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria.

Höglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, Mollenhauer B, Müller U, Nilsson C, Whitwell JL, Arzberger T, Englund E, Gelpi E, Giese A, Irwin DJ, Meissner WG, Pantelyat A, Rajput A, van Swieten JC, Troakes C, Antonini A, Bhatia KP, Bordelon Y, Compta Y, Corvol JC, Colosimo C, Dickson DW, Dodel R, Ferguson L, Grossman M, Kassubek J, Krismer F, Levin J, Lorenzl S, Morris HR, Nestor P, Oertel WH, Poewe W, Rabinovici G, Rowe JB, Schellenberg GD, Seppi K, van Eimeren T, Wenning GK, Boxer AL, Golbe LI, Litvan I; Movement Disorder Society-endorsed PSP Study Group.

Mov Disord. 2017 Jun;32(6):853-864. doi: 10.1002/mds.26987. Epub 2017 May 3.

PMID:
28467028
4.

Study of LRRK2 variation in tauopathy: Progressive supranuclear palsy and corticobasal degeneration.

Sanchez-Contreras M, Heckman MG, Tacik P, Diehl N, Brown PH, Soto-Ortolaza AI, Christopher EA, Walton RL, Ross OA, Golbe LI, Graff-Radford N, Wszolek ZK, Dickson DW, Rademakers R.

Mov Disord. 2017 Jan;32(1):115-123. doi: 10.1002/mds.26815. Epub 2016 Oct 6.

PMID:
27709685
5.

A geographical cluster of progressive supranuclear palsy in northern France.

Caparros-Lefebvre D, Golbe LI, Deramecourt V, Maurage CA, Huin V, Buée-Scherrer V, Obriot H, Sablonnière B, Caparros F, Buée L, Lees AJ.

Neurology. 2015 Oct 13;85(15):1293-300. doi: 10.1212/WNL.0000000000001997. Epub 2015 Sep 9.

6.

Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy.

Kouri N, Ross OA, Dombroski B, Younkin CS, Serie DJ, Soto-Ortolaza A, Baker M, Finch NC, Yoon H, Kim J, Fujioka S, McLean CA, Ghetti B, Spina S, Cantwell LB, Farlow MR, Grafman J, Huey ED, Ryung Han M, Beecher S, Geller ET, Kretzschmar HA, Roeber S, Gearing M, Juncos JL, Vonsattel JP, Van Deerlin VM, Grossman M, Hurtig HI, Gross RG, Arnold SE, Trojanowski JQ, Lee VM, Wenning GK, White CL, Höglinger GU, Müller U, Devlin B, Golbe LI, Crook J, Parisi JE, Boeve BF, Josephs KA, Wszolek ZK, Uitti RJ, Graff-Radford NR, Litvan I, Younkin SG, Wang LS, Ertekin-Taner N, Rademakers R, Hakonarsen H, Schellenberg GD, Dickson DW.

Nat Commun. 2015 Jun 16;6:7247. doi: 10.1038/ncomms8247.

7.

Progressive supranuclear palsy.

Golbe LI.

Semin Neurol. 2014 Apr;34(2):151-9. doi: 10.1055/s-0034-1381736. Epub 2014 Jun 25. Review.

PMID:
24963674
8.

Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial.

Boxer AL, Lang AE, Grossman M, Knopman DS, Miller BL, Schneider LS, Doody RS, Lees A, Golbe LI, Williams DR, Corvol JC, Ludolph A, Burn D, Lorenzl S, Litvan I, Roberson ED, Höglinger GU, Koestler M, Jack CR Jr, Van Deerlin V, Randolph C, Lobach IV, Heuer HW, Gozes I, Parker L, Whitaker S, Hirman J, Stewart AJ, Gold M, Morimoto BH; AL-108-231 Investigators.

Lancet Neurol. 2014 Jul;13(7):676-85. doi: 10.1016/S1474-4422(14)70088-2. Epub 2014 May 27.

9.

The tau of PSP: a long road to treatment.

Golbe LI.

Mov Disord. 2014 Apr;29(4):431-4. doi: 10.1002/mds.25855. Epub 2014 Mar 1. No abstract available.

PMID:
24585428
10.

Diversity of pathological features other than Lewy bodies in familial Parkinson's disease due to SNCA mutations.

Fujishiro H, Imamura AY, Lin WL, Uchikado H, Mark MH, Golbe LI, Markopoulou K, Wszolek ZK, Dickson DW.

Am J Neurodegener Dis. 2013 Nov 29;2(4):266-75. eCollection 2013.

11.

Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations.

Soldner F, Laganière J, Cheng AW, Hockemeyer D, Gao Q, Alagappan R, Khurana V, Golbe LI, Myers RH, Lindquist S, Zhang L, Guschin D, Fong LK, Vu BJ, Meng X, Urnov FD, Rebar EJ, Gregory PD, Zhang HS, Jaenisch R.

Cell. 2011 Jul 22;146(2):318-31. doi: 10.1016/j.cell.2011.06.019. Epub 2011 Jul 14. Erratum in: Cell. 2011 Aug 19;146(4):659.

12.

Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy.

Höglinger GU, Melhem NM, Dickson DW, Sleiman PM, Wang LS, Klei L, Rademakers R, de Silva R, Litvan I, Riley DE, van Swieten JC, Heutink P, Wszolek ZK, Uitti RJ, Vandrovcova J, Hurtig HI, Gross RG, Maetzler W, Goldwurm S, Tolosa E, Borroni B, Pastor P; PSP Genetics Study Group, Cantwell LB, Han MR, Dillman A, van der Brug MP, Gibbs JR, Cookson MR, Hernandez DG, Singleton AB, Farrer MJ, Yu CE, Golbe LI, Revesz T, Hardy J, Lees AJ, Devlin B, Hakonarson H, Müller U, Schellenberg GD.

Nat Genet. 2011 Jun 19;43(7):699-705. doi: 10.1038/ng.859.

13.

Movement disorders and pregnancy: a review of the literature.

Kranick SM, Mowry EM, Colcher A, Horn S, Golbe LI.

Mov Disord. 2010 Apr 30;25(6):665-71. doi: 10.1002/mds.23071. Review.

PMID:
20437535
14.

Early diagnosis of progressive supranuclear palsy: bucking the odds.

Golbe LI.

Neurology. 2008 Nov 25;71(22):1754-5. doi: 10.1212/01.wnl.0000338701.59007.ee. No abstract available.

PMID:
19029515
15.

The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study.

Latourelle JC, Sun M, Lew MF, Suchowersky O, Klein C, Golbe LI, Mark MH, Growdon JH, Wooten GF, Watts RL, Guttman M, Racette BA, Perlmutter JS, Ahmed A, Shill HA, Singer C, Goldwurm S, Pezzoli G, Zini M, Saint-Hilaire MH, Hendricks AE, Williamson S, Nagle MW, Wilk JB, Massood T, Huskey KW, Laramie JM, DeStefano AL, Baker KB, Itin I, Litvan I, Nicholson G, Corbett A, Nance M, Drasby E, Isaacson S, Burn DJ, Chinnery PF, Pramstaller PP, Al-hinti J, Moller AT, Ostergaard K, Sherman SJ, Roxburgh R, Snow B, Slevin JT, Cambi F, Gusella JF, Myers RH.

BMC Med. 2008 Nov 5;6:32. doi: 10.1186/1741-7015-6-32.

16.

Huntington CAG repeat size does not modify onset age in familial Parkinson's disease: the GenePD study.

McNicoll CF, Latourelle JC, MacDonald ME, Lew MF, Suchowersky O, Klein C, Golbe LI, Mark MH, Growdon JH, Wooten GF, Watts RL, Guttman M, Racette BA, Perlmutter JS, Ahmed A, Shill HA, Singer C, Saint-Hilaire MH, Massood T, Huskey KW, DeStefano AL, Gillis T, Mysore J, Goldwurm S, Pezzoli G, Baker KB, Itin I, Litvan I, Nicholson G, Corbett A, Nance M, Drasby E, Isaacson S, Burn DJ, Chinnery PF, Pramstaller PP, Al-Hinti J, Moller AT, Ostergaard K, Sherman SJ, Roxburgh R, Snow B, Slevin JT, Cambi F, Gusella JF, Myers RH.

Mov Disord. 2008 Aug 15;23(11):1596-601. doi: 10.1002/mds.22186.

17.

The epidemiology of progressive supranuclear palsy.

Golbe LI.

Handb Clin Neurol. 2008;89:457-9. doi: 10.1016/S0072-9752(07)01242-0. No abstract available.

PMID:
18631768
18.

Replication of association between ELAVL4 and Parkinson disease: the GenePD study.

DeStefano AL, Latourelle J, Lew MF, Suchowersky O, Klein C, Golbe LI, Mark MH, Growdon JH, Wooten GF, Watts R, Guttman M, Racette BA, Perlmutter JS, Marlor L, Shill HA, Singer C, Goldwurm S, Pezzoli G, Saint-Hilaire MH, Hendricks AE, Gower A, Williamson S, Nagle MW, Wilk JB, Massood T, Huskey KW, Baker KB, Itin I, Litvan I, Nicholson G, Corbett A, Nance M, Drasby E, Isaacson S, Burn DJ, Chinnery PF, Pramstaller PP, Al-Hinti J, Moller AT, Ostergaard K, Sherman SJ, Roxburgh R, Snow B, Slevin JT, Cambi F, Gusella JF, Myers RH.

Hum Genet. 2008 Aug;124(1):95-9. doi: 10.1007/s00439-008-0526-4. Epub 2008 Jun 29.

19.

Haplotypes and gene expression implicate the MAPT region for Parkinson disease: the GenePD Study.

Tobin JE, Latourelle JC, Lew MF, Klein C, Suchowersky O, Shill HA, Golbe LI, Mark MH, Growdon JH, Wooten GF, Racette BA, Perlmutter JS, Watts R, Guttman M, Baker KB, Goldwurm S, Pezzoli G, Singer C, Saint-Hilaire MH, Hendricks AE, Williamson S, Nagle MW, Wilk JB, Massood T, Laramie JM, DeStefano AL, Litvan I, Nicholson G, Corbett A, Isaacson S, Burn DJ, Chinnery PF, Pramstaller PP, Sherman S, Al-hinti J, Drasby E, Nance M, Moller AT, Ostergaard K, Roxburgh R, Snow B, Slevin JT, Cambi F, Gusella JF, Myers RH.

Neurology. 2008 Jul 1;71(1):28-34. doi: 10.1212/01.wnl.0000304051.01650.23. Epub 2008 May 28.

20.

A clinical rating scale for progressive supranuclear palsy.

Golbe LI, Ohman-Strickland PA.

Brain. 2007 Jun;130(Pt 6):1552-65. Epub 2007 Apr 2.

PMID:
17405767

Supplemental Content

Loading ...
Support Center